Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
Original title: “Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues”
Regimen update recommended across all indications
Original title: “Libtayo dosing backed by CHMP”
New Frankfurt site to boost long-term supply
Original title: “Sanofi breaks ground on new insulin facility”
teclistamab induced a profound hematologic response in light chain deposition disease with probable cardiac involvement
Original title: “Teclistamab Induced a Profound Hematologic Response in Light Chain Deposition Disease With Probable Cardiac Involvement.”
The Lysosomal Storage Disorders Support Society appeals to Prime Minister Narendra Modi for urgent funding to support patients facing treatment interruptions due to exhausted financial assistance under the National Policy for Rare Diseases. The letter emphasizes the necessity for a ... The Lysosomal Storage Disorders Support Society appeals to Prime Minister Narendra Modi for urgent funding to support patients facing treatment interruptions due to exhausted financial assistance under the National Policy for Rare Diseases. The letter emphasizes the necessity for a continuity-of-treatment mechanism to aid those suffering from life-threatening conditions, particularly children with ultra-rare diseases. It said 164 patients had exhausted the financial assistance available under NPRD, 2021, of whom around 115 were patients suffering from ultra-rare LSDs, including Gaucher and Pompe disease. ... Many of these patients are children as young as two, three, four or five years of age, it added. LSDSS appealed to urgently reinstate treatment for all clinically eligible patients and to establish an interim funding arrangement until the matter is sub judice before the Supreme Court. It added that a continuity-of-treatment mechanism must be established under NPRD to fill a structural gap in the implementation of the policy. LSDSS said, “A mechanism is urgently required so that a patient requiring lifelong or long-term therapy is not abruptly rendered ineligible merely because the prescribed financial ceiling has been reached.” · It also urged that children and patients at high clinical risk must be prioritised for treatment and that all concerned Centres of Excellence must be directed to identify and report such patients immediately. LSDSS said patients with progressive, potentially life-threatening conditions were facing treatment interruptions after exhausting their sanctioned financial assistance.
Original title: “Patients with Rare Diseases Urge Prime Minister Modi for Additional Treatment Funding, ETHealthworld”
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
Original title: “Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep”
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
Original title: “Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep”
The global clinical trials market was valued at an estimated USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, expanding at a compound annual growth rate of 7.7% from 2026 to 2033. According to the report, market growth is supported by the rising prevalence of chronic and rare diseases, increasing demand for innovative therapies... The global clinical trials market was valued at an estimated USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, expanding at a compound annual growth rate of 7.7% from 2026 to 2033. According to the report, market growth is supported by the rising prevalence of chronic and rare diseases, increasing demand for innovative therapies, advances in biotechnology and precision medicine, and higher research and development investment from pharmaceutical and biopharmaceutical companies. New Report puts the global market at $89bn in 2025, with chronic and rare disease, precision medicine and outsourcing to contract researchers driving... It evaluates current clinical trials industry trends and market opportunities across phase, study design, indication, indication by study design, service, sponsor, and region. Phase: Phase I, Phase II, Phase III, and Phase IV. Study design: Interventional trials, observational trials, and expanded access trials. Indication: Autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, cardiovascular diseases, and other therapeutic areas. The indication-by-study-design analysis assesses interventional, observational, and expanded access trials across autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, cardiovascular diseases, and additional indications. This structure enables stakeholders to compare revenue potential and clinical research activity across major therapeutic and study categories.
Original title: “Global Clinical Trials Market Size, Share, Trends, and Forecast, 2026-2033 | Market to Reach USD 158.4 Billion at 7.7% CAGR as Decentralized Trials and R&D Outsourcing Accelerate”
Saudi Arabia’s biotech strategy now has named partners, sites and capital behind it.
Original title: “From strategy to scale: How Saudi Arabia is building a biotech ecosystem”
Explore extractables data supporting single-use systems in ADC manufacturing.
Original title: “Extractables in single-use systems used in ADC manufacturing”
Discover which CMC activities can move forward early, and which decisions need to remain flexible.
Original title: “How early should you engage a CDMO?”
transition of rare and or complex conditions from paediatric to adult care use of the itg form and outcome analysis
Original title: “Transition of Rare and/or Complex Conditions From Paediatric to Adult Care: Use of the ITG Form and Outcome Analysis.”